ORG 26576

Drug Profile

ORG 26576

Alternative Names: ORG26576

Latest Information Update: 17 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Merck & Co
  • Class Isoxazoles
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 20 Jun 2008 Phase-I/II clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
  • 20 Jun 2008 Phase-I/II clinical trials in Depression in USA (PO)
  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top